Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World Outcomes of Aflibercept Biosimilar MY-1701P Treatment in Exudative Age-Related Macular Degeneration

NCT07235527 is registered in ClinicalTrials.gov with Saglik Bilimleri Universitesi as lead sponsor.

NCT NCT07235527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07235527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World Outcomes of Aflibercept Biosimilar MY-1701P Treatment in Exudative Age-Related Macular Degeneration
Lead sponsor
Saglik Bilimleri Universitesi
Phase
Observational
Overall status
Completed
Start date
November 20, 2025
Completion date
August 30, 2026
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration, anti vascular endothelial growth factor, exudative age-related macular degeneration